WO2005091937A2 - Compositions useful for the treatment of microbial infections - Google Patents

Compositions useful for the treatment of microbial infections Download PDF

Info

Publication number
WO2005091937A2
WO2005091937A2 PCT/US2005/006761 US2005006761W WO2005091937A2 WO 2005091937 A2 WO2005091937 A2 WO 2005091937A2 US 2005006761 W US2005006761 W US 2005006761W WO 2005091937 A2 WO2005091937 A2 WO 2005091937A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
kurarinone
berberine
group
microorganism
Prior art date
Application number
PCT/US2005/006761
Other languages
French (fr)
Other versions
WO2005091937A3 (en
Inventor
Wenyuan Shi
Li Chen
Qing-Yi Lu
David Heber
Maxwell H. Anderson
Original Assignee
The Regents Of The University Of California
C3 Scientific Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, C3 Scientific Corporation filed Critical The Regents Of The University Of California
Publication of WO2005091937A2 publication Critical patent/WO2005091937A2/en
Publication of WO2005091937A3 publication Critical patent/WO2005091937A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489Sophora, e.g. necklacepod or mamani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/535Perilla (beefsteak plant)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718Coptis (goldthread)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/896Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/361Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9789Magnoliopsida [dicotyledons]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783Angiosperms [Magnoliophyta]
    • A61K8/9794Liliopsida [monocotyledons]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • a suitable carrier can be an aqueous carrier including any safe and effective materials for use in the compositions of the present invention.
  • an aqueous carrier is used for the compositions of the present invention in oral formations and includes, without limitation, thickening materials, humectants, water, buffering agents, abrasive polishing materials, surfactants, titanium dioxide, flavor system, sweetening agents, coloring agents, and mixtures thereof.
  • Dioscin has a strong anti-fungal activity. Its MIC for C. albicans is around 4 ⁇ g/ml. 2. Dioscin has a fungicidal effect. 3. Clinical isolated drug-resistant C. albicans are still sensitive to the dioscin treatment.

Abstract

The present invention is based on the discovery that certain chemical compounds isolated from Chinese medicinal herbs are useful as anti-microbial agents, e.g., anti­bacterial agents, anti-fungal agents, and the like. In particular, the present invention provides compositions useful for treating microbial infections such as, for example, oral microbial infections, including periodontal disease and dental caries.

Description

COMPOSITIONS USEFUL FOR THE TREATMENT OF MICROBIAL INFECTIONS
FIELD OF THE INVENTION [0001] The invention relates generally to treatment of microorganisms, and more specifically to compositions isolated from herbs useful in treating microbial infections.
BACKGROUND INFORMATION
[0002] Modern medical science is constantly searching for new and more powerful agents to prevent, treat or retard bacterial and viral infections and cure the diseases they cause. Bacterial and viral infections of humans and domestic animals cost billions of dollars annually. Vast sums of money are spent each year by pharmaceutical companies to identify, characterize, and produce new antibiotics and antivirals to combat the emerging drug resistant strains which have become a serious problem. Reliable prophylactic treatments for disease prevention are also of major interest.
[0003] Specifically periodontal disease and dental caries are of major public health and economic interest worldwide. It is now widely recognized that both of these oral diseases are caused by bacteria which grow in masses on the teeth and in the gingival and subgingival areas. A commonly used descriptive term for these bacterial masses is "dental plaque". In the case of periodontal disease, it has been reported that dental plaque bacteria, growing in the area where the teeth and gingival tissues meet, cause an inflammation of the gingiva called "gingivitis". This is characterized by swollen, edematous gingiva ("gums") which are reddened and bleed easily. If plaque removal is inadequate, gingivitis may progress to "periodontitis" or periodontal disease in some individuals. Periodontitis generally is characterized by a chronic inflammation of the tissues around the teeth, which leads to a resorption of supporting bone. Periodontal disease is the leading cause of tooth loss among adults.
[0004] Dental caries (cavities) are also caused by bacteria, with mutans Streptococcus being the principal etiologic agent. Dental caries is a prevalent and costly disease throughout the world. The latest report by NIH indicated that 49% of 12-year-old and 79% of 17-year-old children in the USA have dental caries. A very high percentage of the elderly also have tooth decay manifest as root caries.
[0005] Tooth decay is mainly caused by a group of cariogenic Gram-positive bacteria such as Streptococcus mutans. Given a suitable carbohydrate nutrient (simple dimer sugars like sucrose), these bacteria produce insoluble glucans and acids in dental plaque. The glucans produced by S. mutans are very sticky, enabling it to adhere to the tooth's surface while the acids attack the tooth's mineral structure causing demineralization that may lead to cavitation.
[0006] The prevention of dental plaque or the removal thereof has long been the focus of development, with the ultimate goal of inhibiting both caries and periodontal diseases. While the formation of dental plaque can be inhibited to a certain extent by brushing the teeth at frequent intervals, brushing alone is not sufficient to effectively prevent the formation of dental plaque or remove substantially all of the dental plaque that has formed on the teeth. Since brushing alone is often not sufficient to prevent dental caries or periodontal disease due to the nature of the pathogenic plaque bacteria, chemical methods using anti-bacterials such as chlorhexidine, benzalkonium chloride, and cetylpyridinium chloride have been proposed.
[0007] There is a need in the art to provide compositions and methods useful for treating or preventing microbial conditions, e.g., oral or mucosal surface microbial conditions.
SUMMARY OF THE INVENTION
[0008] The present invention is based on the discovery that certain chemical compounds isolated from Chinese medicinal herbs are useful as anti-microbial agents, e.g., antibacterial agents, anti-fungal agents, agents capable of disrupting bacterial quorum sensing, and the like. In particular, the present invention provides compositions and methods useful for inhibiting the activity of microorganisms and/or treating microbial infections such as, for example, oral or mucosal surface microbial infections. [0009] In one embodiment, the present invention provides a composition comprising at least two compounds selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
[00010] In another embodiment, the present invention provides a composition comprising perillaldehyde and at least one compound selected from the group consisting of kurarinone, berberine, dioscin, α-linolenic acid, and polyphyllin D.
[00011] In yet another embodiment, the present invention provides a composition comprising polyphyllin D and at least one compound selected from the group consisting of kurarinone, berberine, α-linolenic acid, and perillaldehyde.
[00012] In still another embodiment, the present invention provides a composition comprising dioscin and at least one compound selected from the group consisting of kurarinone, berberine, α-linolenic acid, and perillaldehyde.
[00013] In another embodiment, the present invention provides a composition comprising kurarinone, berberine, dioscin, and α-linolenic acid.
[00014] In another embodiment, the present invention provides a composition comprising kurarinone, berberine, α-linolenic acid, and polyphyllin D.
[00015] In yet another embodiment, the present invention provides a pharmaceutical composition comprising an active component and a pharmaceutically acceptable carrier, wherein the active component consists at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
[0001 ] In yet another embodiment, the present invention provides a pharmaceutical composition comprising an active component and a pharmaceutically acceptable carrier, wherein the active component comprises perillaldehyde and at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D. [00017] In still another embodiment, the present invention provides a formulation suitable for topical administration comprising the composition of the present invention.
[00018] In yet another embodiment, the present invention provides an oral hygiene product comprising the composition of the present invention.
[00019] In yet another embodiment, the present invention provides a food additive composition comprising the composition of the present invention.
[00020] In another embodiment, the present invention provides a method of inhibiting the activity of a microorganism. The method comprises contacting the microorganism with a composition of at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
[00021] In yet another embodiment, the present invention provides a method of treating or preventing a microbial infection. The method comprises administering to a subject in need of such treatment a composition comprising at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
[00022] In yet another embodiment, the present invention provides a method of preventing a microbial infection. The method comprises contacting a composition to an area susceptible to a microorganism causing the microbial infection, wherein the composition comprises at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
DETAILED DESCRIPTION OF THE INVENTION
[0010] The present invention is based on the discovery that certain chemical compounds isolated from Chinese medicinal herbs are useful as anti-microbial agents, e.g., antibacterial agents, anti-fungal agents, agents capable of disrupting bacterial quorum sensing, and the like. Accordingly, the present invention provides compositions and methods useful for inhibiting the activity of microorganisms and/or treating microbial infections such as, for example, oral or mucosal surface microbial infections. [0011] In particular, six compounds from four medicinal Chinese herbs have been isolated and found to have anti-microbial activity. Specifically, kurarinone has been isolated from the herb Sophoraflavescens; berberine has been isolated from the herb Coptis chinensis; α-linolenic acid and perillaldehyde have been isolated from the herb Perilla frutescens; and polyphyllin D and dioscin have been isolated from the herb Paris polyphylla.
[0012] These six compounds have the following structures:
Figure imgf000006_0001
kurarinone (Formula I)
Figure imgf000006_0002
berberine (Formula II)
Figure imgf000006_0003
α-LinoIenic acid (Formula III)
Figure imgf000007_0001
perillaldehyde (Formula IV)
Figure imgf000007_0002
polyphyllin D (Formula V)
Figure imgf000007_0003
dioscin (Formula VI)
[0013] According to one feature of the present invention, it provides compositions useful for treating microorganisms, e.g., inhibiting the activity of microorganisms. The composition of the present invention includes at least one, two, three or four compounds of a group of compounds isolated from herbs, e.g., Chinese medicinal herbs of Sophora flavescens, Coptis chinensis, Perilla frutescens, and Paris polyphylla. [0014] In one embodiment, the composition of the present invention includes at least one, two, three, or four compounds of a group of compounds comprised of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D. According to the present invention, the compound of kurarinone, berberine, α-linolenic acid, perillaldehyde, polyphyllin D, or dioscin includes any naturally existing or chemically synthesized original compound, e.g., compound having the chemical structure as shown in Formula I (ACS No. 34981-26-5), II (ACS No. 2086-83-1), in (ACS No. 463-40-1), IV (ACS No. 2111-75-3), V (ACS No. 50773-41-6), or VI (ACS No. 19057-60-4), respectively and any derivatives thereof, excluding any naturally existing herbs containing one or more original compounds such as Sophoraflavescens, Coptis chinensis, Perilla frutescens, and Paris polyphylla. For example, the original compound of kurarinone, berberine, α-linolenic acid, perillaldehyde, polyphyllin D and dioscin is 1) 2-(2,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-5- methoxy-8-[5-methyl-2-(l -methylethenyl)-4-hexenyl]-4H- 1 -benzopyran-4-one, 2) 5,6- dihydro-9,10-dimethoxy-benzo[g]-l,3-benzodioxolo[5,6 a]quinolizinium, 3) (9Z,12Z,15Z)- 9,12,15-octadecatrienoic acid, 4) 4-(l-methylethenyl)-l-cyclohexene-l-carboxaldehyde, 5) (3β,25R)-spirost-5-en-3-yl O-α-L-arabinofuranosyl-(l→-4)-O-[6-deoxy-α-L- mannopyranosyl-(l- 2)]-β-D-glucopyranoside, and 6) (3β,25R)-spirost-5-en-3-yl O-6- deoxy-α-L-mannopyranosyl-(l→^2)-O-[6-deoxy-α-L-mannopyranosyl-(l— 4)]-β-D- glucopyranoside, respectively.
[0015] Derivatives of these original compounds include any compounds obtainable via modifying the original compounds of kurarinone, berberine, α-linolenic acid, perillaldehyde, polyphyllin D, or dioscin or any compound containing one or more key structural features of these original compounds, provided that these compounds still maintain the same or different level of anti-microbial activity contained within the original compounds. In addition, the compound of kurarinone, berberine, α-linolenic acid, perillaldehyde, polyphyllin D, or dioscin can be in any form, e.g., salt, including without any limitation, hydrochloride, bisulfate, sulfate, etc.
[0016] In another embodiment, the composition of the present invention includes a compound capable of enhancing the anti-microbial activity of another compound and at least one, two, or three compounds having anti-microbial activity. For example, the composition of the present invention can include perillaldehyde and at least one, two, or three compounds of a group of compounds comprised of kurarinone, berberine, dioscin, α- linolenic acid, and polyphyllin D.
[0017] In yet another embodiment, the composition of the present invention includes a compound with anti-fungal activity and at least one compound with anti-bacterial activity. For example, the composition of the present invention can include polyphyllin D and at least one compound of a group of compounds comprised of kurarinone, berberine, α- linolenic acid, and perillaldehyde. Alternatively the composition of the present invention can include dioscin and at least one compound of a group of compounds comprised of kurarinone, berberine, α-linolenic acid, and perillaldehyde.
[0018] In still another embodiment, the composition of the present invention includes at least kurarinone, berberine, dioscin, and α-linolenic acid, or kurarinone, berberine, α- linolenic acid and polyphyllin D.
[0019] According to another feature of the present invention, the composition of the present invention is a pharmaceutical composition, e.g., useful for inhibiting the activity of microorganisms or treating microbial infection. The pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier and one or more active components derived from compounds isolated from herbs e.g., Chinese medicinal herbs of Sophoraflavescens, Coptis chinensis, Perilla frutescens, and Paris polyphylla.
[0020] In one embodiment, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier and an active component including at least one, two, three, or four compounds of a group of compounds comprised of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
[0021] In another embodiment, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier and an active component including compounds derived from herbs, but not from other sources. For example, the pharmaceutical composition of the present invention can include a pharmaceutically acceptable carrier and an active component derived solely from kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and/or polyphyllin D, e.g., an active component including at least one, two, three, or four compounds of a group of compounds comprised of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
[0022] In yet another embodiment, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier and an active component including a compound having anti-fungal activity and a compound having anti-bacterial activity. For example, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier and an active component including polyphyllin D or dioscin and at least one compound selected from the group of kurarinone, berberine, perillaldehyde, and α-linolenic acid.
[0023] In still another embodiment, the pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier and an active component including a compound capable of enhancing the anti-microbial activity of other compounds and at least one compound with anti-microbial activity. For example, the pharmaceutical composition of the present invention can include a pharmaceutically acceptable carrier and an active component including perillaldehyde and at least one, two, three or four compounds selected from the group of polyphyllin D, dioscin, kurarinone, berberine, and α- linolenic acid.
[0024] The composition or pharmaceutical composition of the present invention can also be provided as a formulation suitable for topical administration, oral hygiene product, or food additive. In addition, the composition of the present invention can also include one or more other non-active ingredients, e.g., ingredients that do not interfere with the function of the active ingredients. For example, the compositions of the present invention can additionally contain any of a variety of added components, such as, for example, preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorings, buffers, coating agents, antioxidants, diluents, and the like. In addition, the composition of the present invention can include a suitable carrier or be combined with other therapeutic agents.
[0025] A suitable carrier can be an aqueous carrier including any safe and effective materials for use in the compositions of the present invention. In one embodiment, an aqueous carrier is used for the compositions of the present invention in oral formations and includes, without limitation, thickening materials, humectants, water, buffering agents, abrasive polishing materials, surfactants, titanium dioxide, flavor system, sweetening agents, coloring agents, and mixtures thereof.
[0026] A suitable carrier can also be a pharmaceutically acceptable carrier that is well known to those in the art, e.g., large, slowly metabolized macromolecules, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. A pharmaceutically acceptable carrier can be a solid carrier or a liquid carrier. Examples of solid carriers include lactose, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid, or lower alkyl ethers of cellulose. Examples of liquid carriers include syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene or water. The carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or distearate, alone or mixed with a wax.
[0027] Pharmaceutically acceptable salts can also be used in the composition, for example, mineral salts such as sodium or stannous fluorides, or sulfates, as well as the salts of organic acids such as acetates, proprionates, carbonates, malonates, or benzoates. The composition can also contain liquids, e.g., water, saline, glycerol, and ethanol, as well as substances, e.g., wetting agents, emulsifying agents, or pH buffering agents.
[0028] If a solid carrier is used for oral administration, the preparation may be tabletted or placed in a hard gelatin capsule in powder or pellet form. The amount of solid carrier will vary widely, but will usually be from about 25 mg to about 1 gm. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution, and the like.
[0029] Tablets are prepared by mixing compositions of the present invention with pharmaceutically inert, inorganic or organic carrier, diluents, and/or excipients. Examples of such excipients which can be used for the preparation of tablets include lactose, maize starch or derivatives thereof, talc, stearic acid or salts thereof. Examples of suitable excipients for gelatin capsules include vegetable oils, waxes, fats, semisolid, and liquid polyols. The lipid analogs can also be made in microencapsulated form.
[0030] For nasal administration, the preparation may contain compositions of the invention dissolved or suspended in a liquid carrier, in particular, an aqueous carrier, for aerosol application. The carrier may contain solubilizing agents such as propylene glycol, surfactants, absorption enhancers such as lecithin or cyclodextrin, or preservatives.
[0031] The present invention embraces the use of pharmaceutical compositions for containing pharmaceutically acceptable sterile aqueous or non-aqueous liquids, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use parenteral injection. Pharmaceutical formulations containing compounds of the present invention can be prepared by conventional techniques, e.g., as described in Remington's Pharmaceutical Sciences, 1985.
[0032] The compositions of the present invention usually have an anti-microbial effect, e.g., anti-G+ bacteria activity, anti-G" bacteria activity, anti-fungus activity or effect on bacterial quorum sensing. Methods or assays for testing the anti-microbial activity of a composition are readily available to one skilled in the art. For example, compositions of the present invention can be incubated with a bacterial or fungous culture, and the bacterial or fungous growth can be subsequently examined with a plate reader. Compositions of the present invention can also be examined for their effect on bacterial quorum sensing using either an acyl-homoserine lactone quorum sensing reporter system or a luxS quorum sensing reporter system. [0033] According to another feature of the present invention, the compositions of the present invention can be used to treat or prevent microbial growth or infection, e.g., inhibit the activity of bacteria or fungi in vivo or in vitro. For example, the compositions of the present invention can be used to inhibit microbial flora, especially microbial flora associated with dental structures such as tooth surface or subsurface or caries, e.g., microbial flora associated with demineralized areas, white spots, pits, and fissures or microbial flora associated with mucosal surfaces.
[0034] In one embodiment, the compositions of the present invention can be used to inhibit microorganisms including without limitation S. mutans, S. sohrinus, S. aureus, L. acidophilus, L. casei, L. plantarum, A. naeslundii, A. viscosus, Actinobacillus actinomycetemcomitants, Porphyromonas gingivalis, Enterococci, Fusobacterium nucleatum, Treponema denticola, Bacteroides forsythus, Candidas albicans, C. glabrata, C. guilliemondii, C. kejyr, C. krusei, C. stellatoidea and C. tropicalis.
[0035] In another embodiment, the composition of the present invention can be used to inhibit the activity of cariogenic bacteria, including without limitation, Mutans streptococci, lactobacilli and actinomyces, e.g., S. mutans, S. sobrinus, A. viscosus, A. naeslundii, L. acidophilus, L. casei, and L. plantarum. In yet another embodiment, the composition of the present invention can be used to inhibit the activity of fungi, e.g., Candidas albicans, C. glabrata, C. guilliemondii, C. kejyr, C krusei, C. stellatoidea and C. tropicalis.
[0036] In still another embodiment, the composition of the present invention can be used to inhibit the activity of drug resistant microorganisms. According to the present invention, a drug resistant microorganism is a microorganism that does not substantially respond to a routinely used antibiotic or respond to an extent below the average response induced by a routinely used antibiotic. For example, the composition of the present invention can be used to treat methicillin resistant S. aureus, Nancomycin resistant Enterococci, or clinically isolated drug resistant C. albicans. In still yet another embodiment, the composition of the present invention containing at least kurarinone can be used to treat methicillin resistant S. aureus and Nancomycin resistant Enterococci while the composition of the present invention containing at least polyphyllin D can be used to treat drug-resistant C. albicans. [0037] According to another feature of the present invention, it provides a method of inhibiting the activity of microorganisms from one or more species or preventing a microbial infection by contacting one or more compositions of the present invention to the microorganisms. The present invention also provides a method for treating or preventing a microbial infection by administering to a subject in need of such treatment an effective amount of one or more compositions of the present invention. The subject in need of such treatment can be any suitable subject, e.g., a human or an animal including a domestic animal such as a horse, dog, or cat. The microbial infection can be any infection caused by one or more microorganisms of one or more species including without limitation microbial infections associated with drug resistant microorganisms, e.g., S. aureus, Enterococci, and C. albicans and/or multi-species biofilms.
[0038] In generally, an effective amount of the compositions to be administered can be determined on a case-by-case basis. Factors to be considered usually include age, body weight, stage of the condition, other disease conditions, duration of the treatment, and the response to the initial treatment. The term "effective amount" as applied to the compositions of the present invention is an amount that will prevent or inhibit the disorders associated with microbial infections noted above. The selected dosage will vary depending on the activity of the selected compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, for example, two to four doses per day.
[0039] Typically, the compositions are prepared as a topical or an injectable, either as a liquid solution or suspension. However, solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection can also be prepared. The composition can also be formulated into tablets, e.g., an enteric-coated tablet, capsules, e.g., gel capsules, emulsions, inhaled liquid or solid particles, microencapsulated particles, e.g., as a spray, or transdermal patches according to known methods in the art.
[0040] The compositions of the present invention may be administered in any way which is medically acceptable which may depend on the condition or injury being treated. Possible administration routes include injections, by parenteral routes such as intravascular, intravenous, intraepidural or others, as well as oral, nasal, ophthalmic, rectal, vaginal, topical, or pulmonary, e.g., by inhalation. The compositions may also be directly applied to tissue surfaces. Sustained release, pH dependent release, or other specific chemical or environmental condition mediated release administration is also specifically included in the invention, by such means as depot injections or erodible implants.
[0041] In one embodiment, the composition of the present invention can be used to treat or prevent microbial infections associated with epithelial tissues or skins, e.g., wounds, burns, acne, fungus infection on skins such as foot, and other skin conditions or with opportunistic organisms, e.g., opportunistic organisms superinfect a site.
[0042] In another embodiment, the composition of the present invention can be used to treat or prevent microbial infections on mucosal surfaces, e.g., mouth, vagina, gastrointestinal (GI) tract, esophageal tract, and respiratory tract. For example, the composition of the present invention can be used to treat or prevent Streptococcus throat, Streptococcus pneumoniae, nontypeable Haemophϊlius influenza, oxMoraxella cararrhalis infection commonly found in acute otitis media (AOM) and otitis media effusion (OME) as complications of upper respiratory infections in young children.
[0043] In another example, the composition of the present invention can be used to treat 1 or prevent GI tract infections including without limitation duodenal or gastric ulcers associated with Helicobacter pylori (H. pylori) bacteria infection, campylobacter bacterial infection, diarrhea primarily associated with Campylobacter jejuni, cholera caused by Vibrio cholerae serogroups, salmonellosis caused by bacteria salmonella such as S. Typhimurium and S. Enteritidis, shigellosis caused by bacteria Shigella, e.g., Shigella dysenteriae and traveler's diarrhea caused by enterotoxi genie Escherichia coli (ETEC) and Clostridium dijjicile infection.
[0044] In yet another example, the composition of the present invention can be used to treat yeast or Candida infections (Candidiasis) typically occur either orally (Oropharyngeal Candida or OPC) or vaginally (Nulvovaginal Candida or NNC). [0045] According to another embodiment of the present invention, the compositions of the present invention are used to treat or prevent cariogenic organism infections, e.g., S. mutans infection associated with dental caries, including without limitation tooth surface or subsurface associated with demineralized areas, white spots, pits, and fissures. One or more compositions of the present invention can be prepared as additives to food, oral hygiene product, or any products having direct contact to an oral environment, especially an oral environment susceptible to dental caries or periodontal diseases. For instance, to treat or prevent dental caries or periodontal diseases compositions of the present invention can be formulated into a baby formula, mouthwash, lozenges, gel, varnish, toothpaste, toothpicks, tooth brushes, or other tooth cleansing devices, localized delivery devices such as sustained release polymers or microcapsules, oral irrigation solutions of any kind whether mechanically delivered or as oral rinses, pacifiers, and any food including, without limitation, chewing gums, candies, drinks, breads, cookies, and milk.
[0046] The invention will now be described in greater detail by reference to the following non-limiting examples.
EXAMPLE 1 Isolation of 'Kurarinone jrom Sophoraflavescens [0047] Sophoraflavescens is one of the common medicinal herbs used by Traditional Chinese Medicine (TCM) doctors. In traditional practice, it has been used to alleviate heat, toxin, constipation, and masses, and to disperse painful swelling in the throat, mouth, and gums. Recently, in vitro pharmacological studies indicated that the extract of Sophora flavescens constitutes a variety of biomedical activities for inflammation, cancer, and cardiovascular disorders.
[0048] The following steps were applied to purify the active compound(s) for structure analysis: 1) the crude extract of Sophora flavescens was suspended in 10% methanol; 2) the aqueous solution was extracted with ethyl acetate; 3) the organic layers were concentrated at 40 °C under reduced pressure; 4) the extract was then chromatographed over silica gel (500 grams), 100-200 mesh (Selecto, George), eluted with gradient hexane:ethyl acetate; 5) the most active fractions were pooled and then further purified by HPLC (Waters, 600E system controller and Waters996 Photodiode Array Detector, Millord, MA). Waters SymmetryPrep C-l 8 column (4.6 X 250 mm). Through bio-assay oriented chemical analysis, it was found that the major anti -bacterial compound isolated from this herb is kurarinone.
Figure imgf000017_0001
Exact Mas 436 19 M l Wt 436 50 m/c 43619(1000%), 43719 (296%), 43820 (42%), 43819(12%) C, 7154, H, 647, O, 2199
[0049] This study of purified kurarinone demonstrated that kurarinone has a strong antibacterial activity, for example, its MIC for S. mutans is 4 μg/ml. The compound also has a bactericidal effect. In addition, the antimicrobial activity of this compound is insensitive to the following environmental changes: pH (4.8-7.4); salt composition (Na, K, Ca); salt concentrations; oxygen levels (anaerobic and aerobic); and temperature (120 °C). Finally, both methicillin resistant Staphylococcus aureus and Nancomycin resistant Enterococci are sensitive to this compound.
EXAMPLE 2
Isolation oj a-linolenic acid and perillaldehyde from Perillae jolium(Suye, SY) [0050] Perillae folium is a flower commonly seen in Japan and China. It is believed to have power in clear fish and crab poisoning and relieve cough. It is used with other herbs in herbal bath for its oil. It also counteracts fatigue and acts as a preventive against dysentery.
[0051] Perilla was selected for two types of bioactivity. The first is a weak antibacterial activity identified through conventional antibacterial assay. The second is its ability to enhance other antibacterial activities through some kind of synergistic effect. When the crude extract was mixed with antibiotics in the bioassay, it could enhance the activity of other antibiotics at a concentration at least 10 times lower than its MIC.
[0052] Bioassay-based phytochemical analyses were conducted to isolate and characterize the active components from SY. The active components were purified from the crude SY extract by hexane extraction and chromatograph through silica gel. The most active fractions were pooled and then further purified by HPLC. Two active compounds were isolated from this herb. Structure analysis demonstrated that one is α-linolenic acid and the other is perillaldehyde.
Figure imgf000018_0001
α-Linolenic acid
[0053] Our study of linolenic acid demonstrated:
1) Linolenic acid has a strong growth inhibitory effect against S. mutans. Its MIC for S. mutans is 10 μg/ml. 2) Linolenic acid is known as one of the major components of perilla oil.
Figure imgf000019_0001
[0054] Our study on perillaldehyde demonstrated:
1). The compound has a weak anti-bacterial activity (MIC for S. mutans: 10 mg/ml). 2). The compound has the ability to enhance activity of other antibiotics in a dose- dependent manner.
EXAMPLE 3
Isolation of polyphyllin D and dioscin from Paris polyphylla (QY)
[0055] Topical application of Paris polyphylla has been well documented in TCM practice. In a preliminary screening, a strong anti-fungal activity was identified. Two active compounds, polyphyllin D and diosocin, were isolated from this herb. For the purpose of structure analysis, purity is the primary concern in this study. Due to this concern, the yield of polyphyllin is low. Clearly, a simple and economic protocol is required for the production of both refined extract and the compound with a defined purity.
[0056] The first step of the purification is ethyl acetate extraction. The crude extract of QY was directly dissolved in ethyl acetate with sonication. The extract (QYEA) was concentrated under reduced pressure in a vacuum rotavapor. The yield of this step is around 0.5%). The recovery rate of total bioactivity is around 40%.
[0057] The QYEA (20 grams) was then chromatographed over silica gel (500 grams), 100-200 mesh (Selecto, George), eluted with gradient hexane:ethyl acetate: methanol (from 100:100: lO.to 100:100: 50). The yield of this step is around 10%. The recovery rate of total bioactivity is around 45%. The extract is labeled as QYEA-Si. [0058] The active fraction was then further purified by HPLC (Waters, 600E system controller and Waters996 Photodiode Array Detector, Millord, MA). Waters SymmetryPrep C-18 column (4.6 X 250 mm) and the following gradient were used for this purpose.
Time Flow rate (minutes) (ml/minute) Acetonitrile% Water% 1 2.00 10 90 2 10 2.00 45 55 3 35 2.00 65 45 4 37 2.00 10 90 5 45 2.00 10 90
Bioassays were conducted to further characterize these two compounds.
Figure imgf000020_0001
C 4H706 Exact Mass: 854.47 Mol. Wt: 855.02 [0059] Studies of polyphyllin D indicated:
1. Polyphyllin D has a strong anti-fungal activity. Its MIC for C. albicans is around 2 μg ml.t 2. Polyphyllin D has a fungicidal effect. 3. Clinical isolated drug-resistant C. albicans are still sensitive to the Polyphyllin treatment.
Figure imgf000021_0001
C45H72θ16 Exact Mass: 868.48 Mol. Wt: 869.04 m/e: 868.48 (100.0%), 869.49 (51.8%), 870.49 (16.3%), 871.49 (3.8%) C, 62.19; H, 8.35; 0, 29.46
[0060] Studies of dioscin indicated:
1. Dioscin has a strong anti-fungal activity. Its MIC for C. albicans is around 4 μg/ml. 2. Dioscin has a fungicidal effect. 3. Clinical isolated drug-resistant C. albicans are still sensitive to the dioscin treatment. [0061] Although the invention has been described with reference to the above example, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.

Claims

WHAT IS CLAIMED IS:
1. A composition comprising at least two compounds selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
2. The composition of claim 1, wherein the composition comprises at least three compounds selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
3. The composition of claim 1, wherein the composition comprises at least four compounds selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
4. A composition comprising perillaldehyde and at least one compound selected from the group consisting of kurarinone, berberine, dioscin, α-linolenic acid, and polyphyllin D.
5. A composition comprising polyphyllin D and at least one compound selected from the group consisting of kurarinone, berberine, α-linolenic acid, and perillaldehyde.
6. A composition comprising dioscin and at least one compound selected from the group consisting of kurarinone, berberine, α-linolenic acid, and perillaldehyde.
7. A composition comprising kurarinone, berberine, dioscin, and α-linolenic acid.
8. A composition comprising kurarinone, berberine, α-linolenic acid, and polyphyllin D.
9. A pharmaceutical composition comprising an active component and a pharmaceutically acceptable carrier, wherein the active component consists at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
10. The pharmaceutical composition of claim 9, wherein the active component comprises at least two compounds selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
11. The pharmaceutical composition of claim 9, wherein the active component comprises at least three compounds selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
12. The pharmaceutical composition of claim 9, wherein the active component comprises at least four compounds selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
13. A pharmaceutical composition comprising an active component and a pharmaceutically acceptable carrier, wherein the active component comprises perillaldehyde and at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
14. A formulation suitable for topical administration comprising the composition of claim 1.
15. A formulation suitable for topical administration comprising the composition of claim 9.
16. An oral hygiene product comprising the composition of claim 1.
17. An oral hygiene product comprising the composition of claim 9.
18. A food additive composition comprising the composition of claim 1.
19. A food additive composition comprising the composition of claim 9.
20. The composition of claim 1, wherein the composition has an anti-microbial effect on a microorganism selected from the group consisting of Gram positive bacteria, Gram negative bacteria, and yeast.
21. The composition of claim 1, wherein the composition has an anti-microbial effect on a microorganism selected from the group consisting of S. mutans, S. sobrinus, S. aureus, L. acidophilus, L. casei, L. plantarum, A. naeslundii, A. viscosus, Actinobacillus actinomycetemcomitants, Porphyromonas gingivalis, Enterococci, Fusobacterium nucleatum, Treponema denticola, Bacteroides forsythus, Candidas albicans, C. glabrata, C. guilliemondii, C. kejyr, C. krusei, C. stellatoidea and C. tropicalis.
22. The composition of claim 1, wherein the composition has an anti-microbial effect on a drug resistant microorganism.
23. The composition of claim 1, wherein the composition has an anti-microbial effect on a drug resistant S. aureus, Enterococci, and C. albicans.
24. The composition of claim 9, wherein the composition has an anti-microbial effect
I on a microorganism selected from the group consisting of Gram positive bacteria, Gram negative bacteria, and yeast.
25. The composition of claim 9, wherein the composition has an anti-microbial effect on a microorganism selected from the group consisting of S. mutans, S. sobrinus, S. aureus, L. acidophilus, L. casei, L. plantarum, A. naeslundii, A. viscosus, Actinobacillus actinomycetemcomitants, Porphyromonas gingivalis, Enterococci, Fusobacterium nucleatum, Treponema denticola, Bacteroides forsythus, Candidas albicans, C. glabrata, C. guilliemondii, C. kejyr, C. krusei, C. stellatoidea and C. tropicalis.
26. The composition of claim 9, wherein the composition has an anti-microbial effect on a drug resistant microorganism.
27. The composition of claim 9, wherein the composition has an anti-microbial effect on a drug resistant S. aureus, Enterococci, and C. albicans.
28. A method of inhibiting the activity of a microorganism comprising contacting the microorganism with a composition of at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
29. The method claim 28, wherein the composition comprises perillaldehyde and at least one compound selected from the group consisting of kurarinone, berberine, dioscin, α-linolenic acid, and polyphyllin D.
30. The method of claim 28, wherein the microorganism is an oral pathogenic microorganism.
31. The method of claim 28, wherein the microorganism causes dental caries or periodontal disease.
32. The method of claim 28, wherein the microorganism is on a mucosal surface.
33. The method of claim 28, wherein the microorganism is associated with a tooth structure.
34. The method of claim 28, wherein the microorganism is associated with an infection in an epithelial tissue.
35. The method of claim 28, wherein the microorganism is a drug resistant microorganism.
36. The method of claim 28, wherein the microorganism is a drug resistant S. aureus, Enterococci, and C. albicans.
37. A method of treating or preventing a microbial infection comprising administering to a subject in need of such treatment a composition comprising at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
38. The method of claim 37, wherein the composition comprises perillaldehyde and at least one compound selected from the group consisting of kurarinone, berberine, dioscin, α-linolenic acid, and polyphyllin D.
39. The method of claim 37, wherein the microbial infection is associated with a drug resistant microorganism.
40. The method of claim 37, wherein the microbial infection is associated with a drug resistant S. aureus, Enterococci, or C. albicans.
41. A method of preventing a microbial infection comprising contacting a composition to an area susceptible to a microorganism causing the microbial infection, wherein the composition comprises at least one compound selected from the group consisting of kurarinone, berberine, dioscin, perillaldehyde, α-linolenic acid, and polyphyllin D.
42. The method of claim 41, wherein the composition comprises perillaldehyde and at least one compound selected from the group consisting of kurarinone, berberine, dioscin, α-linolenic acid, and polyphyllin D.
43. The method of claim 41, wherein the microorganism causing the microbial infection I is a drug resistant microorganism.
44. The method of claim 41, wherein the microorganism causing the microbial infection is a drug resistant S. aureus, Enterococci, or C. albicans.
PCT/US2005/006761 2004-03-04 2005-03-02 Compositions useful for the treatment of microbial infections WO2005091937A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/795,554 2004-03-04
US10/795,554 US7875598B2 (en) 2004-03-04 2004-03-04 Compositions useful for the treatment of microbial infections

Publications (2)

Publication Number Publication Date
WO2005091937A2 true WO2005091937A2 (en) 2005-10-06
WO2005091937A3 WO2005091937A3 (en) 2006-03-30

Family

ID=35056693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/006761 WO2005091937A2 (en) 2004-03-04 2005-03-02 Compositions useful for the treatment of microbial infections

Country Status (2)

Country Link
US (1) US7875598B2 (en)
WO (1) WO2005091937A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7875598B2 (en) 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections
ES2490815T3 (en) 2006-09-06 2014-09-04 The Regents Of The University Of California Selectively directed antimicrobial peptides and their use
EP2118122B1 (en) * 2007-01-16 2015-09-23 The Regents of The University of California Novel antimicrobial peptides
US20110098495A1 (en) * 2009-10-27 2011-04-28 Chifu Huang Compositions and methods of omega polyunsaturated fatty acids for the treatment of oral diseases
KR101751486B1 (en) * 2016-03-02 2017-06-28 광주과학기술원 Composition for Enhancing BKCa Channel
JP2023542023A (en) * 2020-09-28 2023-10-04 ザ プロクター アンド ギャンブル カンパニー Oral care compositions containing prenylated flavonoids
CN112175884B (en) * 2020-10-29 2022-04-15 北京农学院 Lactobacillus plantarum SD26 and product and application thereof
CN116440149A (en) * 2022-03-15 2023-07-18 中国科学院昆明植物研究所 Application of rhizoma paridis saponin in preparing dermatophyte resisting product

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198724A (en) * 1998-01-28 2000-07-18 Pola Chem Ind Inc Skin-beautifying preparation for external use for skin
US6346267B1 (en) * 2000-07-07 2002-02-12 Wakunaga Of America Co., Ltd. Composition and method for treatment of symptoms associated with insufficient estrogen production
US20020102316A1 (en) * 2000-12-01 2002-08-01 Weissman Glenn H. Composition and method for treating snoring
CN1415301A (en) * 2002-11-12 2003-05-07 蔡海德 Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application
US20030211185A1 (en) * 2001-12-12 2003-11-13 ALEXIS Brian Natural, anti-bacterial, anti-virus, anti-herpes cream
WO2004028519A1 (en) * 2002-09-26 2004-04-08 Mandom Corporation Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5221571B2 (en) * 1972-12-18 1977-06-11
US4324782A (en) 1974-01-28 1982-04-13 Beck Lee R Dental caries inhibiting product of immunized cow's milk having antibodies specific to killed Streptococcus mutans cells
US4150116A (en) 1978-02-21 1979-04-17 Forsyth Dental Infirmary For Children Immunization against dental caries with glucosyltransferase antigens
ZA794413B (en) 1978-09-01 1980-08-27 Us Government Protection against dental caries
US4250262A (en) 1979-12-14 1981-02-10 Forsyth Dental Infirmary For Children Method of preparing a purified glucosyltransferase
AU556184B2 (en) 1981-06-19 1986-10-23 Secretary of State For Social Services in Her Britanic Majestys Government of the United Kingdom of Great Britain and Northern Ireland Protection against dental caries.
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
JPS6028937A (en) 1983-07-25 1985-02-14 Kitasato Inst:The Noncariogenic antibody and composition
US4693888A (en) 1983-08-11 1987-09-15 Lion Corporation Caries-preventive composition
JPS6038329A (en) 1983-08-11 1985-02-27 Lion Corp Preventive for dental caries
JPH0641424B2 (en) 1984-11-06 1994-06-01 ライオン株式会社 Caries preventive agent
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US5352446A (en) 1986-03-25 1994-10-04 Council Of Governors Of The United Medical And Dental Schools Of Guy's And St. Thomas's Hospitals Method of treating dental caries with monoclonal antibodies against the antigen I and antigen I/II of streptococcus mutans
US5518721A (en) 1987-02-27 1996-05-21 Council Of Governors Of The United Medical And Dental Schools Of Guy's And St. Thomas Hospital Antibodies against Streptococcus
US5281524A (en) 1988-01-22 1994-01-25 Kanebo, Ltd. Cell-associated glucosyltransferase from Streptococcus mutans serotype, c, e or f
JP2641228B2 (en) 1988-01-22 1997-08-13 鐘紡株式会社 Antibody, caries preventive agent containing the same as an active ingredient, and methods for producing the same
US5851527A (en) 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
JPH02177899A (en) 1988-12-28 1990-07-10 Nagase Sangyo Kk Igd monoclonal antibody specifically reactive with streptococcus mutans
NO902352L (en) 1989-05-29 1990-11-30 Lion Corp PROCEDURE FOR THE PREPARATION OF A VACCINE AGAINST DENTAL KARIES, AND VACCINE MIXTURES FOR USE AS NOSE KILLS
US5332567A (en) 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
US6197299B1 (en) 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
US5981726A (en) 1990-10-12 1999-11-09 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5646119A (en) 1991-11-01 1997-07-08 Periodontix, Inc. D-amino acid histatin-based peptides as anti-fungal and anti-bacterial agents
JPH05227916A (en) 1992-01-11 1993-09-07 Kanebo Ltd Dental caries preventing food
RU2128709C1 (en) 1992-01-23 1999-04-10 Мерк Патент Гмбх Method of preparing dimeric single-chain fused protein (variants)
JPH07506374A (en) 1992-05-01 1995-07-13 フォーシス デンタル インファーマリー フォー チルドレン Synthetic peptide vaccine for caries prevention
US5726293A (en) 1992-10-02 1998-03-10 The General Hospital Corporation Affinity purification methods involving imidazole elution
JPH06122633A (en) 1992-10-09 1994-05-06 Lion Corp Antibody having immunoactivity on streptococcus mutans and dental caries preventive
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE69528445D1 (en) 1994-12-12 2002-11-07 Unilever Nv Anti-microbial agent
US6046037A (en) 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
AU716989B2 (en) 1996-04-16 2000-03-16 Novozymes A/S Compositions for the removal of dental plaque
US5891422A (en) 1996-10-10 1999-04-06 Warner-Lambert Company Antimicrobial composition containing a C3 -C6 alcohol
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6455031B1 (en) 1997-06-18 2002-09-24 David G Davies Methods and compositions for controlling biofilm development
US5875798A (en) 1997-09-23 1999-03-02 Advanced Medical Instruments, Inc. Therapeutic toothpick for treating oral and systemic diseases
US5874068A (en) 1997-12-08 1999-02-23 Warner-Lambert Company Stabilized antiplaque and antigingivitis oral compositions containing N.sup.α -alkyl-L-arginine alkyl ester salts
US6303575B1 (en) 1998-05-12 2001-10-16 The Regents Of The University Of California Indolicidin analogs and methods of using same
US6673900B2 (en) 1999-11-04 2004-01-06 University College London Polypeptide hormone-phosphatonin
JP4731687B2 (en) 1998-08-21 2011-07-27 ザ リージェンツ オブ ザ ユニヴァーシティ オブ カリフォルニア Monoclonal antibodies specific for Streptococcus mutans and uses thereof
US6231857B1 (en) 1998-09-28 2001-05-15 The Regents Of The University Of California Antibodies to S. mutans and uses thereof
US20040052814A1 (en) 1998-09-28 2004-03-18 Wenyuan Shi Fusion proteins for targeted delivery of antimicrobial peptides
US6309835B1 (en) 1999-05-27 2001-10-30 Koninkiijke Philips Electronics N.V. Methods for quantitating the efficacy of oral care products
US20020068066A1 (en) 1999-08-20 2002-06-06 Wenyuan Shi Method for the treatment and prevention of dental caries
US7569542B2 (en) 1999-08-20 2009-08-04 The Regents Of The University Of California Anti-microbial targeting chimeric pharmaceutical
US20030143234A1 (en) 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
JP2003532698A (en) 2000-05-10 2003-11-05 プリンストン ユニバーシティ Compounds and methods for regulating bacterial growth and pathogenesis
US6492328B2 (en) 2000-06-28 2002-12-10 The University Of Iowa Research Foundation Novispirins: antimicrobial peptides
AU2000270698A1 (en) 2000-08-24 2002-03-04 Regents Of The Universtiy Of California Immunologic method for the prevention of dental caries
AU2001291049A1 (en) 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
AUPR575401A0 (en) 2001-06-18 2001-07-12 Unisearch Limited Method of causing sloughing
IL145767A (en) * 2001-10-04 2006-10-31 Israel State Microbicidal formulation comprising an essential oil or its derivatives
US20040023254A1 (en) 2002-01-08 2004-02-05 Fuhrmann Jeffry J. Method to assess quorum sensing potential of microbial communities
WO2003078576A2 (en) 2002-03-12 2003-09-25 Nitto Denko Corporation Vector for transfection of eukaryotic cells
WO2003093314A2 (en) 2002-05-03 2003-11-13 Millenium Biologix Inc. Connective tissue stimulating peptides
US20030228379A1 (en) * 2002-05-28 2003-12-11 Wenyuan Shi Herbs and herbal combinations useful for the treatment of microbial infections
US7427408B2 (en) 2002-06-06 2008-09-23 The Regents Of The University Of California Quorum sensing and biofilm formation
US7875598B2 (en) 2004-03-04 2011-01-25 The Regents Of The University Of California Compositions useful for the treatment of microbial infections

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000198724A (en) * 1998-01-28 2000-07-18 Pola Chem Ind Inc Skin-beautifying preparation for external use for skin
US6346267B1 (en) * 2000-07-07 2002-02-12 Wakunaga Of America Co., Ltd. Composition and method for treatment of symptoms associated with insufficient estrogen production
US20020102316A1 (en) * 2000-12-01 2002-08-01 Weissman Glenn H. Composition and method for treating snoring
US20030211185A1 (en) * 2001-12-12 2003-11-13 ALEXIS Brian Natural, anti-bacterial, anti-virus, anti-herpes cream
WO2004028519A1 (en) * 2002-09-26 2004-04-08 Mandom Corporation Antiseptic bactericides and cosmetics, drugs and foods containing the antiseptic bactericides
CN1415301A (en) * 2002-11-12 2003-05-07 蔡海德 Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases

Also Published As

Publication number Publication date
US7875598B2 (en) 2011-01-25
US20060135498A1 (en) 2006-06-22
WO2005091937A3 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
WO2005091937A2 (en) Compositions useful for the treatment of microbial infections
WO2018062605A1 (en) Toothpaste composition containing galenical extract
KR102408893B1 (en) Composition for prevention or treatment of oral disease comprising Pueraria Extract
KR20170141053A (en) Composition for prevention or treatment of dental disease comprising an extract of Gardenia jasminoides
KR102562835B1 (en) Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract
KR100492034B1 (en) Antibacterial agent and oral composition for preventing and treating caries and periodontal disease containing panduratin derivatives
JPH04164021A (en) Composition for oral cavity
Karic et al. Effectiveness of Allium sativum on bacterial oral infection
KR20190138518A (en) Composition for prevention or trreatment of dental disease comprising an extract of Thalictrum aquilegiifolium
KR20190080504A (en) Composition for the prevention and improvement of Periodontal Disease
KR20170141034A (en) Composition for prevention or treatment of dental disease comprising Panax ginseng extract
KR20170141027A (en) Composition for prevention or treatment of dental disease comprising an extract of Astragalus membranaceus
KR20170141030A (en) Composition for prevention or treatment of dental disease comprising cistanoside A
KR101634210B1 (en) Composition for preventing or treating cavity and periodontal disease comprising kaempferol as effective component
KR102415612B1 (en) Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract
KR101574678B1 (en) Composition for preventing or treating periodontal disease comprising Lactuca scariola extract as effective component
Al-Dabbagh et al. Comparison of antimicrobial activity of four herbal extracts against streptococcus mutans, isolated from dental diseases in vitro
WO2016080666A2 (en) Composition for preventing or treating dental caries and periodontal disease, containing extract of ambrosia trifida l. or fraction thereof as active ingredient
KR102511133B1 (en) Composition for Inhibiting Biofilm Formation Comprising Extracts of Coptis chinensis
KR101392810B1 (en) Antibacterial compositions containing plant extracts or fractions
KR20170141057A (en) Composition for prevention or treatment of dental disease comprising an extract of Daphne genkwa
Sharma et al. Laboratory Evaluation Of The Efficacy Of Formulated Polyherbal Toothpaste “Oralis S” On Dental Caries In Rats
Eidi et al. Therapeutic Activity of Salvia officinalis L. Hydro‐Ethanolic Extract from Aerial Parts on Dental Disease
Srisawat Effect of some Thai medicinal plant extracts on antibacterial activity of periodontopathic bacteria and their anti-inflammatory activity and toxicity to gingival connective tissue fibroblast
KR102115575B1 (en) Composition for prevention or treatment of oral disease comprising extracts of Artemisiae Annuae and Bamboo salts

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase